{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:51:45Z","timestamp":1793681505989,"version":"4.5.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF\/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD&amp;gt;24, defined as POD &amp;gt;24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF\/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD&amp;gt;24. Median OS2 was inferior in patients with early POD (defined as PRF\/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF\/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD&amp;gt;24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004765","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T20:09:25Z","timestamp":1631563765000},"page":"5179-5189","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David A.","family":"Bond","sequence":"first","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-9325","authenticated-orcid":false,"given":"Jeffrey M.","family":"Switchenko","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;"},{"name":"Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Churnetski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;"},{"name":"Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subir","family":"Goyal","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Shanmugasundaram","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Calzada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-9855","authenticated-orcid":false,"given":"Bhaskar","family":"Kolla","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Gerson","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA;"},{"name":"Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA;"},{"name":"Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute,Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH;"},{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute,Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Weill Cornell Medical Center\/New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-8462","authenticated-orcid":false,"given":"Edward","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health Sciences University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-4451","authenticated-orcid":false,"given":"Max","family":"Gordon","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health Sciences University, Portland, OR;"},{"name":"Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health Sciences University, Portland, OR;"},{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mathews","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-0564","authenticated-orcid":false,"given":"Madelyn","family":"Burkart","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Division of Hematology, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Division of Hematology, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Atrium Health, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Park","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Atrium Health, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"BMT Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Guo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Weill Cornell Medical Center\/New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"BMT Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"BMT Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-4675","authenticated-orcid":false,"given":"Mary-Kate","family":"Malecek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"},{"name":"Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"issue":"5","key":"2021120716260814900_B1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br J Haematol."},{"issue":"4","key":"2021120716260814900_B2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer."},{"issue":"10044","key":"2021120716260814900_B3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet."},{"issue":"6","key":"2021120716260814900_B4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021120716260814900_B5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"issue":"7","key":"2021120716260814900_B6","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood."},{"issue":"20","key":"2021120716260814900_B7","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/bloodadvances.2019000526","article-title":"Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma","volume":"3","author":"Kamdar","year":"2019","journal-title":"Blood Adv."},{"issue":"5","key":"2021120716260814900_B8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv."},{"issue":"15","key":"2021120716260814900_B9","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/bloodadvances.2020002068","article-title":"Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma","volume":"4","author":"Villa","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2021120716260814900_B10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood."},{"issue":"8","key":"2021120716260814900_B11","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood."},{"issue":"13","key":"2021120716260814900_B12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021120716260814900_B13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2021120716260814900_B14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood."},{"issue":"17","key":"2021120716260814900_B15","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood."},{"issue":"11","key":"2021120716260814900_B16","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer."},{"issue":"23","key":"2021120716260814900_B17","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study [published correction appears in J Clin Oncol. 2016;34(12):1430]","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021120716260814900_B18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood."},{"issue":"6","key":"2021120716260814900_B19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.25473","article-title":"The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas","volume":"94","author":"Tracy","year":"2019","journal-title":"Am J Hematol."},{"issue":"8","key":"2021120716260814900_B20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood."},{"issue":"27","key":"2021120716260814900_B21","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol."},{"issue":"5","key":"2021120716260814900_B22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD Study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021120716260814900_B23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021120716260814900_B24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol."},{"issue":"5","key":"2021120716260814900_B25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol."},{"issue":"4","key":"2021120716260814900_B26","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3109\/10428194.2013.815349","article-title":"Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database","volume":"55","author":"Salek","year":"2014","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2021120716260814900_B27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","article-title":"Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma","volume":"21","author":"Schaffel","year":"2010","journal-title":"Ann Oncol."},{"issue":"2","key":"2021120716260814900_B28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol."},{"issue":"6","key":"2021120716260814900_B29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica."},{"issue":"10","key":"2021120716260814900_B30","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol."},{"issue":"3","key":"2021120716260814900_B31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol."},{"issue":"5","key":"2021120716260814900_B32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2019002385","article-title":"Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing","volume":"136","author":"Pararajalingam","year":"2020","journal-title":"Blood."},{"key":"2021120716260814900_B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129563","article-title":"Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution [abstract]","volume":"134","author":"Joffe","year":"2019","journal-title":"Blood."},{"issue":"6","key":"2021120716260814900_B34","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica."},{"key":"2021120716260814900_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124691","article-title":"Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed\/refractory mantle cell lymphoma with up to 7.5 years of extended follow-up [abstract]","volume":"134","author":"Rule","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2021120716260814900_B36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study [published correction appears in Leukemia. 2021;35(3):932]","volume":"35","author":"Visco","year":"2020","journal-title":"Leukemia."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2025018576","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5179\/1849644\/advancesadv2021004765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5179\/1849644\/advancesadv2021004765.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T16:35:10Z","timestamp":1638894910000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/5179\/476879\/Early-relapse-identifies-MCL-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":36,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004765","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]}}}